Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 20 NOVEMBER 2026

References are made to the notice (the "**Notice**") and the circular (the "**Circular**") of the extraordinary general meeting (the "**EGM**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**") both dated 22 October 2026 and the announcement of the Company dated 6 November 2026 ("**Announcement**") in relation to the postponement of the EGM. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as defined in the Circular and the Announcement.

POLL RESULTS OF THE POSTPONED EGM

The Board is pleased to announce that the proposed resolution (the "**Resolution**") as set out in the Notice was duly passed by the Shareholders by way of poll at the Postponed EGM held on Friday, 20 November 2026.

As at the date of the Postponed EGM, the total number of issued Shares of the Company was 331,740,350 Shares, including 51,669,250 Unlisted Shares and 280,071,100 H Shares. There were (a) no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) as at the date of the Postponed EGM and as such no voting rights of treasury shares have been exercised at the Postponed EGM; and (b) no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the Postponed EGM.

To the best of the knowledge, information and belief of the Directors, no Shareholders were required under the Listing Rules to abstain from voting on the Resolution at the Postponed EGM. No Shareholders were entitled to attend the Postponed EGM but required to abstain from voting on the Resolution pursuant to Rule 13.40 of the Listing Rules. No Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the Resolution at the Postponed EGM.

Tricor Investor Services Limited, the H Share Registrar of the Company, was appointed to act as the scrutineer for the purpose of vote-taking at the Postponed EGM.

The following Director attended the Postponed EGM: Dr. Wang Bing.

The poll results in respect of the Resolution taken at the Postponed EGM are as follows:

SPECIAL RESOLUTION		**Number of votes (% of total number of votes)**		
		FOR	**AGAINST**	**ABSTAIN**
1.	To consider and approve the granting of a general mandate to the Board to repurchase H Shares during the Relevant Period.	263,627,600 (99.99%)	0 (0.00%)	5,200 (0.01%)

Please refer to the Notice for the full text of the Resolution.

As more than two-thirds of the votes were cast in favour of the above Resolution, such Resolution was duly passed as special resolution of the Company by the Shareholders at the Postponed EGM.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 20 November 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.